Medical Reimbursement and Cancer Detection Advances

This chapter explores the shift towards medical reimbursement over FDA approvals in the diagnostics industry, with a focus on a healthcare company's innovations during the COVID-19 pandemic. It discusses the importance of early cancer detection, the role of liquid biopsy technology, and future predictions for reducing cancer mortality rates through advancements in testing.